Over 10 years we help companies reach their financial and branding goals. Maxbizz is a values-driven consulting agency dedicated.

Gallery

Contact

+1-800-456-478-23

411 University St, Seattle

maxbizz@mail.com

Twitter Facebook-f Pinterest-p Instagram

Team

Executive Team

Neal Muni MD, MSPH
CEO

⎖ Dr. Muni is an accomplished life sciences executive with 25 years of industry experience as an operator, investor, and advisor to multiple biotechnology and pharmaceutical companies, leveraging unique insights gained through a career spanning industry, healthcare investment banking, the FDA, and clinical care.
⎖ Dr. Muni served as the CEO of Azurity Pharmaceuticals, a commercial-stage pharmaceutical company focused on developing therapeutics for patients with high unmet need.Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA.

 

Daniel Beard, PhD
CSO

⎖ Senior Lecturer, University of Newcastle, expertise in preclinical cerebrovascular physiology.
⎖ Internationally recognised expert in preclinical stroke models and collateral circulation physiology. Extensive publication record on cerebrovascular physiology and stroke.
⎖ Identified shear-stress as a novel therapeutic target for collateral enhancement, leading to a key collaboration with Professor Donald Ingber at Harvard University.

Netanel Korin, PhD
CTO

⎖ Associate Professor at Technion and Harvard with expertise in biofluid mechanics and localized therapeutics. Head of the Cardiovascular NanoMed Engineering Lab at Technion – Israel Institute of Technology.
⎖ Pioneer in mechano-responsive nanomedicines, leveraging engineering principles for drug delivery. Leader in cardiovascular disease research, focusing on innovative treatment and diagnostic approaches. Expertise in translating bioengineering research into novel therapeutic solutions for biotech startups.

Neil Spratt, FRACP, PhD
CMO

⎖ Professor at the University of Newcastle & John Hunter Hospital, specialising in stroke research. Clinician-researcher, with dual expertise as a clinical neurologist (FRACP, 2003) and basic scientist (PhD, 2007).
⎖ Leads a nationally recognised multidisciplinary stroke research team. Strong experience in clinical trials, imaging technology, and stroke treatment innovations.
⎖ Expert in translating research into clinical practice, to drive new stroke therapies from discovery to implementation.

Board of Directors

Donald Ingber, MD, PhD
Chairman

⎖ Professor & Founding Director of the Wyss Institute of Biologically Inspired Engineering.
⎖ Over 45 years of research in cell & developmental biology, cancer research, vascular biology, and translational medicine. Published 500+ articles with >149,000 citations.
⎖ Founded 8 companies, driving innovation in biotech and medical technology. Licensed multiple drugs, devices, and diagnostics, contributing to healthcare advancements. Actively involved in FDA regulatory review for numerous technologies.

Neal Muni MD, MSPH
Director

⎖ Dr. Muni is an accomplished life sciences executive with 25 years of industry experience as an operator, investor, and advisor to multiple biotechnology and pharmaceutical companies, leveraging unique insights gained through a career spanning industry, healthcare investment banking, the FDA, and clinical care.
⎖ Dr. Muni served as the CEO of Azurity Pharmaceuticals, a commercial-stage pharmaceutical company focused on developing therapeutics for patients with high unmet need.Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA.

 

Daniel Beard, PhD
Director

⎖ Senior Lecturer, University of Newcastle, expertise in preclinical cerebrovascular physiology.
⎖ Internationally recognised expert in preclinical stroke models and collateral circulation physiology. Extensive publication record on cerebrovascular physiology and stroke.
⎖ Identified shear-stress as a novel therapeutic target for collateral enhancement, leading to a key collaboration with Professor Donald Ingber at Harvard University.